Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8.

View in: PubMed

subject areas

Class I Phosphatidylinositol 3-Kinases
Endometrial Neoplasms
Female
Humans
Megestrol Acetate
Mutation
Phosphatidylinositol 3-Kinases
Prospective Studies
Proto-Oncogene Proteins c-akt
PTEN Phosphohydrolase
Sirolimus
Tamoxifen
Tumor Suppressor Proteins

authors with profiles

Gini Fleming